Cytomegalovirus in Allogeneic Hematopoietic Transplantation: Impact on Costs and Clinical Outcomes Using a Preemptive Strategy
Jennifer L Saullo,Yanhong Li,Julia A Messina,Jillian Thompson,Tara Dalton,Vinay K Giri,Shelby D Reed,Rachel Miller,Mitchell E Horwitz,Barbara D Alexander,Anthony D Sung,Jennifer L. Saullo,Julia A. Messina,Vinay K. Giri,Shelby D. Reed,Mitchell E. Horwitz,Barbara D. Alexander,Anthony D. Sung
DOI: https://doi.org/10.1016/j.bbmt.2019.11.005
2020-03-01
Biology of Blood and Marrow Transplantation
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>Cytomegalovirus (CMV) results in significant morbidity and mortality following hematopoietic cell transplantation (HCT). Establishing the cost and clinical impact are imperative to selecting appropriate CMV preventative strategies.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>This is a retrospective cohort study of consecutive patients undergoing their first allogeneic HCT between January 1, 2009 and December 31, 2013. Detailed clinical and institutional cost data were obtained from the start of conditioning through one-year post-transplant. Baseline characteristics, resource utilization, costs and outcomes were compared between patients with and without clinically significant CMV infection (csCMVi).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>One-hundred seventy out of 388 (44%) patients developed csCMVi within one-year following HCT. Within the first post-transplant year, patients with csCMVi had significantly longer transplant lengths of stay (mean 91.7 vs. 78.3 days, p<0.0001) and more frequent and prolonged hospitalizations (mean 2.4 vs. 1.7 admissions, p<0.0001; mean 39.1 vs. 31.5 inpatient days, p=0.001) without significantly more admissions to the intensive care unit (28.2% vs. 21.6%, p=0.408). Use of granulocyte-colony stimulating factor was higher in patients with csCMVi (73.5% vs 54.1%, p=0.0001) though no significant differences were demonstrated in mean platelet or red blood cell transfusions. Total costs were also higher in patients with csCMVi (mean cost difference $45,811 (95% CI $26,385 - $67,544). However, the incidence of graft-versus-host disease (GVHD) and select infectious complications was not significantly different between the groups. There were no significant differences in one- and five-year post-transplant overall survival (OS) nor non-relapse mortality (NRM) between those with or without csCMVi, though relapse of underlying disease was significantly lower in the csCMVi group.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>Allogeneic HCT patients with csCMVi had significantly greater medical resource utilization and costs than those without. However, clinical outcomes including GVHD, infections and mortality were similar in both groups. Future study is needed to determine the cost effectiveness of CMV preventative modalities.</p>
biology